0000914190-21-000037.txt : 20210209 0000914190-21-000037.hdr.sgml : 20210209 20210209172413 ACCESSION NUMBER: 0000914190-21-000037 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210205 FILED AS OF DATE: 20210209 DATE AS OF CHANGE: 20210209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eansor Norman David CENTRAL INDEX KEY: 0001270905 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 21607952 MAIL ADDRESS: STREET 1: 8100 SOUTHPARK WAY, A-8 CITY: LITTLETON STATE: CO ZIP: 80120 FORMER NAME: FORMER CONFORMED NAME: EANSOR N DAVID DATE OF NAME CHANGE: 20031120 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2021-02-05 0000842023 BIO-TECHNE Corp TECH 0001270905 Eansor Norman David 8100 SOUTHPARK WAY, A-8 LITTLETON CO 80120 0 1 0 0 President-Protein Sciences Common Stock 2021-02-05 4 M 0 14114 106.59 A 15432 D Common Stock 2021-02-05 4 M 0 18819 106.59 A 34251 D Common Stock 2021-02-05 4 S 0 6000 378.2871 D 28251 D Common Stock 2021-02-05 4 S 0 4500 379.6249 D 23751 D Common Stock 2021-02-05 4 S 0 12833 380.497 D 10918 D Common Stock 2021-02-05 4 S 0 2900 381.5155 D 8018 D Common Stock 2021-02-05 4 S 0 3700 382.6043 D 4318 D Common Stock 2021-02-05 4 S 0 1900 384.1518 D 2418 D Common Stock 2021-02-05 4 S 0 1100 385.5918 D 1318 D Stock Options (Right to Buy) 106.59 2021-02-05 4 M 0 14114 0 D 2023-08-18 Common Stock 14114 0 D Stock Options (Right to Buy) 106.59 2021-02-05 4 M 0 18819 0 D 2023-08-18 Common Stock 18819 0 D Stock Options (Right to Buy) 125.05 2024-08-09 Common Stock 11982 11982 D Stock Options (Right to Buy) 125.05 2024-08-09 Common Stock 15976 15976 D Restricted Stock Units Common Stock 2537 2537 D Stock Options (Right to Buy) 177.32 2025-08-08 Common Stock 13550 13550 D Stock Options (Right to Buy) 177.32 2025-08-08 Common Stock 18066 18066 D Restricted Stock Units Common Stock 3151 3151 D Stock Options (Right to Buy) 190.41 2026-08-07 Common Stock 15948 15948 D Stock Options (Right to Buy) 190.41 2026-08-07 Common Stock 21265 21265 D Restricted Stock Units Common Stock 2575 2575 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 11488 11488 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 15318 15318 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 24975 24975 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 24975.0 24975.0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $378.00 to $378.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $379.03 to $380.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $380.065 to $381.055, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $381.095 to $382.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $382.26 to $383.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $383.93 to $384.39, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $385.415 to $385.77, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Fully exercisable. Options to purchase 3,994 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021 Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. /s/ Brenda S. Furlow as Attorney-in-Fact for N. David Eansor pursuant to Power of Attorney previously filed. 2021-02-09